Share
array:23 [ "pii" => "S2173578612001333" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2012.02.001" "estado" => "S300" "fechaPublicacion" => "2012-06-01" "aid" => "417" "copyright" => "AEU" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2012;36:333-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1146 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 898 "PDF" => 239 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0210480612000708" "issn" => "02104806" "doi" => "10.1016/j.acuro.2012.02.003" "estado" => "S300" "fechaPublicacion" => "2012-06-01" "aid" => "417" "copyright" => "AEU" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2012;36:333-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 4055 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 3709 "PDF" => 337 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artículo especial</span>" "titulo" => "Variabilidad de la práctica clínica urológica en cáncer de próstata en España" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "333" "paginaFinal" => "339" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Variability of the urological clinical practice in prostate cancer in Spain" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0025" "etiqueta" => "Figura 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1236 "Ancho" => 1569 "Tamanyo" => 65303 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Realidad de uso de hormonoterapia intermitente (sobre 177 encuestados).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "C. Núñez, J. Angulo, M. Sánchez-Chapado, S. Alonso, J.A. Portillo, H. Villavicencio" "autores" => array:6 [ 0 => array:2 [ "nombre" => "C." "apellidos" => "Núñez" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Angulo" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Sánchez-Chapado" ] 3 => array:2 [ "nombre" => "S." "apellidos" => "Alonso" ] 4 => array:2 [ "nombre" => "J.A." "apellidos" => "Portillo" ] 5 => array:2 [ "nombre" => "H." "apellidos" => "Villavicencio" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173578612001333" "doi" => "10.1016/j.acuroe.2012.02.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578612001333?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480612000708?idApp=UINPBA00004N" "url" => "/02104806/0000003600000006/v2_201304261440/S0210480612000708/v2_201304261440/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173578612001345" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2011.11.001" "estado" => "S300" "fechaPublicacion" => "2012-06-01" "aid" => "401" "copyright" => "AEU" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2012;36:340-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1363 "formatos" => array:3 [ "EPUB" => 14 "HTML" => 1075 "PDF" => 274 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Effects of delivery and oophorectomy on urethral collagen: An experimental study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "340" "paginaFinal" => "345" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Efectos del parto y ooforectomía sobre el colágeno uretral: estudio experimental" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1255 "Ancho" => 1667 "Tamanyo" => 222184 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Collagen fibers after staining with picrosirius trichrome histochemical technique, observed under polarized light.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.A. Aranha, R. Tambara-Filho, R. de Fraga, D.A. da Luz-Veronez, E.L. Prisco-Farias, G. Ens" "autores" => array:6 [ 0 => array:2 [ "nombre" => "M.A." "apellidos" => "Aranha" ] 1 => array:2 [ "nombre" => "R." "apellidos" => "Tambara-Filho" ] 2 => array:2 [ "nombre" => "R." "apellidos" => "de Fraga" ] 3 => array:2 [ "nombre" => "D.A." "apellidos" => "da Luz-Veronez" ] 4 => array:2 [ "nombre" => "E.L." "apellidos" => "Prisco-Farias" ] 5 => array:2 [ "nombre" => "G." "apellidos" => "Ens" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210480611004207" "doi" => "10.1016/j.acuro.2011.11.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480611004207?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578612001345?idApp=UINPBA00004N" "url" => "/21735786/0000003600000006/v1_201304251924/S2173578612001345/v1_201304251924/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>" "titulo" => "Variability of the urological clinical practice in prostate cancer in Spain" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "333" "paginaFinal" => "339" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "C. Núñez, J. Angulo, M. Sánchez-Chapado, S. Alonso, J.A. Portillo, H. Villavicencio" "autores" => array:6 [ 0 => array:4 [ "nombre" => "C." "apellidos" => "Núñez" "email" => array:1 [ 0 => "cnunez@mdanderson.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J." "apellidos" => "Angulo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "M." "apellidos" => "Sánchez-Chapado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "S." "apellidos" => "Alonso" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "J.A." "apellidos" => "Portillo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "H." "apellidos" => "Villavicencio" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "MD Anderson Internacional, Madrid, Spain" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Hospital Universitario de Getafe, Universidad Europea de Madrid, Madrid, Spain" "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain" "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Departamento Médico, Abbott Laboratories SA, Madrid, Spain" "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Hospital Universitario Marqués de Valdecilla, Santander, Spain" "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Fundació Puigvert, Barcelona, Spain" "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Variabilidad de la práctica clínica urológica en cáncer de próstata en España" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1187 "Ancho" => 1590 "Tamanyo" => 64135 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Relative indication surgery/radiotherapy in the healthcare practice of the respondents.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Prostate cancer is the most common solid tumor, responsible for 11% of all cancer deaths, but only 20% of the men who have it die from it.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Its clinical approach has been modified in recent years by continuous relevant advances that include aspects related to the prevention and detection of the disease, minimizing the impact on quality of life of the patient due to the disease and its treatment, and the increasingly complex decision-making among the numerous treatment options available.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> This continuous development generates a growing uncertainty in many aspects. In addition, the urologist finds it increasingly complex to maintain a level of knowledge and skills updated enough in their clinical practice, so as to ensure each patient healthcare adequate to the latest evidence and alternatives available.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Like it or not, the actual approach of prostate cancer in Spain is currently undergoing a major variability of professional standards and not well evaluated clinical practice, whose existence deserves special consideration and deep corporate reflection of the urological association. With the aim of exploring the profile of professional skills and clinical habits in managing prostate cancer in urological practice, and identifying possible opportunities for improvement in this area (disclosure, education, training, provision of equipment, optimization of the doctor-patient relationship), a survey posed to a representative portion of the urological association of our country, which addresses the most controversial aspects of the disease and some of the practices most subject to variability in the approach of the disease, has been conducted.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Materials and method</span><p id="par0015" class="elsevierStylePara elsevierViewall">In 2009, we conducted a prospective observational, descriptive and transversal study, through an autofilled survey by a group of Spanish urologists practicing regularly involved in the diagnosis and treatment of prostate cancer in its healthcare environment. The questionnaire posed 137 elements or direct questions. In order to ensure the relevance of the questions and the objectivity of the responses, the questionnaire was submitted to consideration by a group of specialists in the field, several of them signatories of this manuscript, which defined the definitive questions and the keys of the final questionnaire. The specialists involved in conducting the surveys did so voluntarily and anonymously.</p><p id="par0020" class="elsevierStylePara elsevierViewall">All the questions were conducted trying for the answers to be dichotomous, what happened in 85 questions (62% of the questionnaire). Only 3 questions (2.2%) had more than 4 possible answers, where possible reducing the dispersion in the analysis of answers. The answers were structured in 14 specific thematic sections, at the end of which an inquiry was made as to the degree of interest that the professional would have to delve into that topic, obtaining a comparative panel that distinguishes the relative interest depending on the ranges of response and the confidence intervals of the same. Thus, relative differences are established between some topics that may be interpreted as of more or less interest.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The 290 specialists surveyed represent the urological professional association involved in the clinical approach of prostate cancer in Spain. In its definition, the degree of professional experience, scope of work, the contractual relationship with the patient, and the academic nature of the center were taken into account. The response rate collected and correctly transcribed of the forms was 96.9% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>281). This sample allows for the main estimates of the study with sufficient accuracy, assuming a maximum error of ±5.8% for a 95% confidence interval (95% CI) and supposing the most unfavorable distribution of responses to dichotomous survey variables (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>q<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.5).</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Results</span><p id="par0030" class="elsevierStylePara elsevierViewall">The mean age of the participants was 46.9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.6<span class="elsevierStyleHsp" style=""></span>years (median: 47; range: 29–69), and in the distribution by homogeneous age groups, 258 (91.8%) were men and 23 (8.2%) women. The age of women was lower (39<span class="elsevierStyleHsp" style=""></span>years; range: 29–54) than that of men (48<span class="elsevierStyleHsp" style=""></span>years; range: 29–69). The mean practice time was 19.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.5<span class="elsevierStyleHsp" style=""></span>years (range: 1–43). Depending on the type of medical practice, 127 (45.3%) worked in a first-level healthcare environment, and 154 (54.7%) in specialized centers. Regarding the type of practice, 115 (40.9%) worked in public healthcare, 10 (3.6%) in private healthcare, and 156 (55.5%) in a mixed environment. Not all the respondents answered all the questions, extrapolating the results for each specific question to theoretical 100%.</p><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Disease diagnosis</span><p id="par0035" class="elsevierStylePara elsevierViewall">This section addressed epidemiological aspects, the relevance of population screening, the use of PSA and other markers, the use of various imaging studies, and the indication and ways to perform a prostate biopsy. 64.4% of the respondents believe that the data on incidence and mortality of prostate cancer in our environment should be interpreted as reliable, and a ratio as high as 97.9% assume that it is possible to improve the currently available record. On the other hand, 64.2% know the existence of some records of prostate cancer in the autonomous community in which they work.</p><p id="par0040" class="elsevierStylePara elsevierViewall">With regard to population screening programs, 49.6% of the professionals believe necessary to carry out a systematic screening for prostate cancer, and even 23.2% carry it out actively. In fact, 65.5% assume that the routine PSA performance can reduce mortality from the disease. However, 71.1% agree not to practice PSA routinely in the elderly. Interestingly, only 63% report their patients adequately of the risks and benefits involved in getting a PSA. On the other hand, the routine use of PSA ranges (85.4%, 95% CI: 81.2–89.3) and the free PSA fraction (89%, 95% CI: 84.9–93.1) has definitely shifted in the routine care of our country to the PSA density (48.4%; 95% CI: 41.6–55.2) as an element of consideration before the indication of prostate biopsy (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001). With regard to the new imaging modalities, 34.9% use FDG-PET, 19.5% choline PET in their work environment, and 75.4% use MRI. Only 12.8% know the multiparametric study of the prostate by means of endorectal MRI. 25.1% routinely use duplex ultrasound. Only 14.6% of the respondents use bone resorption markers. 38.5% (95% CI: 32.8–44.6) believe that the most promising marker is PC3A versus 14.4% (95% CI: 10.6–19.2) who consider the GDPH methylation study (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05) for this role.</p><p id="par0045" class="elsevierStylePara elsevierViewall">With regard to the technique of biopsy performance, before an initial biopsy, 32.2% usually conduct a sextant biopsy (6 cylinders), 26.3% also include the transitional zone (8 cylinders), and 41.5% practice extended biopsy (with 10–12 cylinders, depending on whether a sample of the transitional zone is taken or not, or more). But, when it comes to a repeat biopsy, the rate of urologists performing sextant biopsy falls to 7%, that of sextants with transitional zone to 19.6%, and that of extended biopsy rises to 73.4% (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). 39.7% use local anesthetic infiltration, and 20.5% take into account the patient's age and the prostate volume to decide the number of cylinders obtained.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Disease prevention</span><p id="par0050" class="elsevierStylePara elsevierViewall">29.5% of the respondents believe that it is possible to carry out drug prevention strategies for prostate cancer, and 21.7% believe that the dutasteride is the appropriate drug for these chemoprophylaxis strategies. 32% believe it is possible to carry out prevention strategies for prostate cancer based on nutritional care. The main candidates are presented and recommended in a non-exclusive manner (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Treatment of the localized disease</span><p id="par0055" class="elsevierStylePara elsevierViewall">With respect to the main therapeutic decision of the localized disease, the professionals take into account the patient's age (97.1%), the overall comorbidity (92.1%), and the fear of the consequences (62.5%). 78.6% offer their patients radiotherapy on an equal basis, but only 18.2% conduct it in an equitable manner (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>). 87.5% of the respondents practice surgery themselves. 72.9% consider brachytherapy, 33.6% LHRH analogue therapy for localized disease, 10% HIFU, 16.5% cryotherapy, and 32.6% watchful waiting (<a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a>) with different criteria to raise the deferred treatment (86.9% PSA elevation, 12.1% development of metastasis, 11.4% other). For the rescue, 59.6% offer hormone therapy (95% CI: 52.6–66.2), 32.3% radiotherapy (95% CI: 26.2–39.1), and 20.7% radical prostatectomy (95% CI: 15.65–26.9), implying significant differences in favor of deferred hormone therapy (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="fig0020"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">Regarding the surgical technique, although 76.1% of the respondents believe in the advantages of laparoscopic radical prostatectomy (LRP), only 26.3% routinely practice it with different frequency. 66.2% of the professionals who do not perform LRP refer being willing to learn the technique. With regard to the robotic approach, the difference between what the urologist considers desirable and their practical reality is even greater, because although 73% of the urologists surveyed believe in the benefits of robot-assisted laparoscopic radical prostatectomy (RALRP), only 1.4% practice it. As for the concept of cost-benefit, 33% (95% CI: 27.7–38.7) and 92.1% (95% CI: 88.35–94.74) of the respondents consider that LRP and RALRP, respectively, are expensive in terms of the alternative of open surgery (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.0001). 10 and 38.27%, respectively, consider that LRP and RALRP should be financed in our health system by the patient holistically.</p><p id="par0065" class="elsevierStylePara elsevierViewall">With regard to the effects of the treatment, 85% of the specialists define themselves as concerned about the sexual sphere of the patient with prostate cancer. In this sense, 88.9% take into account the patient's opinion about their sex life when deciding about treatment of the localized disease. Even in the treatment of disseminated disease, 49.7% consider the patient's opinion in this regard to the point of delaying the indication of hormone treatment if necessary. 68.6% of the respondents practice prostatectomy with erector preservation, and 98.6% of the professionals are involved in the search for the treatment that solves the effect (56.3% actively, and 43.7% only if the patient demands it). 84.9% are concerned about the continence of the patient with prostate cancer, so much so that when this effect occurs, 99.3% participate in the search of the treatment (82.4% actively, and 17.6% only if the patient demands it). 74.3% always recommend pelvic floor exercises, 78.4% consider placing sphincter prosthesis and 63.9% male sling.</p><p id="par0070" class="elsevierStylePara elsevierViewall">68.2% of the respondents believe that it is easy to define biochemical recurrence, both for patients operated and for those treated with radiotherapy, and 75% believe that this situation must be treated actively and early. The treatment decisions collected vary depending on whether it is failed surgery (radiotherapy 36.8%, hormone therapy 20.7%, combination of both 42.5%) or failed radiotherapy (hormone therapy 96%, salvage surgery 2.5%, and salvage cryotherapy 5.4%). No respondents chose expectant management, or for patients operated or radiated.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Treatment of the advanced disease</span><p id="par0075" class="elsevierStylePara elsevierViewall">With regard to hormonal blockade, 69.7% (95% CI: 62.1–74.8) prefer maximum androgen blockade (MAB) versus 30.3% (95% CI: 26.1–34.5) supporter of simple androgen blockade with LHRH analogue alone (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001). As for the best time for the onset of hormone therapy in disseminated disease, 89.5% consider appropriate to start it as early as possible, compared to 10.5% who think that it should be started in a delayed way when there are data of progression or pain. When prescribing a LHRH analogue, the respondents take into account the simplicity in the administration of the preparation (92%), the six-monthly release (87.5%), the easiness of storage at room temperature (81.6%), and the thickness of the needle (81.65%). 42% declare that they have a preference for a particular analogue; of them, 90.5% state the preference for leuproleine acetate as an effective and safe molecule to achieve reliable androgen deprivation. Routine surgical castration is practiced by only 0.7%, and intermittent hormonal therapy with different frequency by 63.7% (<a class="elsevierStyleCrossRef" href="#fig0025">Fig. 5</a>).</p><elsevierMultimedia ident="fig0025"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">In the locally advanced disease, there are differences in the use of neoadjuvant hormone therapy according to the type of definitive treatment: 92.8% (95% CI: 89.5–96.1) systematically consider it before radiotherapy, compared with 35.3% (95% CI: 29.2–41.4) before surgery (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001). Even 21.3% (95% CI: 16.4–26.1) use neoadjuvant treatment in apparently localized tumors that will undergo surgery (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05). Regarding the use of adjuvant hormone therapy, 48.9% (95% CI: 43.4–54.4) consider it after surgery in the cases that prove to be locally advanced in the histopathologic specimen, and 83% (95% CI: 79.1–86.9%) after radiotherapy for high-risk cases (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001). There is great variability about what the appropriate duration of adjuvant hormone therapy is (<a class="elsevierStyleCrossRef" href="#fig0030">Fig. 6</a>).</p><elsevierMultimedia ident="fig0030"></elsevierMultimedia><p id="par0085" class="elsevierStylePara elsevierViewall">In order to detect treatment failures, 82.9% perform regular testosterone controls in patients with hormone blockade, although 34.2% only do it before the PSA increase. 69.9% believe that it is easy to define the castration-resistant disease. In this circumstance, 45.7% (95% CI: 39.2–52) consider giving up the hormonal blockade, 78.8% (95% CI: 75.2–82.4) believe that docetaxel and prednisone are the best treatments, and 77.6% (95% CI: 72.4–82.8) use strategies of second-line hormone therapy, but only 34.4% refer having updated information on new drugs which act that way. In addition, 45.7% (95% CI: 39.9–51.6) use a bisphosphonate routinely in patients with refractory disease. These practices show that secondary hormone manipulation (removing or adding antiandrogen) and initiating docetaxel with prednisone are the most used attitudes to remove LHRH analogue or establish bisphosphonates (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001).</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Defining areas of interest to the professional</span><p id="par0090" class="elsevierStylePara elsevierViewall">The degree of relative interest is collected by the Likert scale for each of the main headings covered by the survey. The main usefulness of this representation is to group the points of different degree of interest according to the overlap of the confidence intervals of the same. This analysis may be seen graphically in <a class="elsevierStyleCrossRef" href="#fig0035">Fig. 7</a>, and relatively in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>, providing levels of interest from 1 (maximum interest) to 5 (minimum interest).</p><elsevierMultimedia ident="fig0035"></elsevierMultimedia><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Discussion</span><p id="par0095" class="elsevierStylePara elsevierViewall">The variability in clinical practice may be determined by lack of awareness of the official recommendations, or because the professionals involved in the analysis of the opinions and views do not agree with the theoretical lines supported and recommended in the documents used as reference.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> So, if there are any deviations in the different fields analyzed, their magnitude will be evaluated with the aim of defining improvement opportunities and analyzing the needs of the national urological association represented by the respondents.</p><p id="par0100" class="elsevierStylePara elsevierViewall">The clinical practice guidelines are very sophisticated documents due to the exhaustive search of data in the literature and the systematization of the same to establish conclusions. The fundamental aspects on which clinical guidelines are currently based are the quality of the evidence and the strength of the recommendations. The <span class="elsevierStyleItalic">Guía de Práctica Clínica sobre Tratamiento de Cáncer de Próstata</span>, published in 2008 by the National Health System,<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> the European Association of Urology Guidelines on Prostate Cancer (<a href="http://www.uroweb.org/professional-resources/guidelines">http://www.uroweb.org/professional-resources/guidelines</a>) updated in 2011,<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7–9</span></a> and the National Comprehensive Cancer Network Guidelines (<a href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp">http://www.nccn.org/professionals/physician_gls/f_guidelines.asp</a>)<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> are the main consensus documents in our clinical practice environment for this disease. It is not intended to compare opinions with recommendations, but to collect the variability detected among the majority opinions and what we accept as consensus, which reflects the view of the experts and the critical reflection of the current literature.</p><p id="par0105" class="elsevierStylePara elsevierViewall">A national registry of prostate cancer that will be used to have own and current data on the prevalence, incidence, and mortality of prostate cancer in Spain is currently being carried out. This point is regarded as one of the topics of greatest relative interest to the respondents. The technical optimization of prostate biopsy is another key point in the diagnosis of the disease. The criteria used are adjusted to a rational pattern, which takes into account whether it is initial or repeat biopsy and, to a lesser extent, the prostate volume and age of the patient. There is little interest in those surveyed in developing new markers and imaging techniques. PCA3 could be useful to identify cancer in men with initially negative biopsies despite an elevated PSA.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> The detection of TMPRSS2-erg fusion genes or the study of abnormal methylation of promoters of various genes in the urine sediment obtained after a prostatic massage.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,13</span></a> The multiparametric study of the prostate by means of MRI with endorectal antenna is also under-considered.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> All these issues are of little interest to specialists in our environment.</p><p id="par0110" class="elsevierStylePara elsevierViewall">The survey includes the areas on which the therapy decision is based in a patient with localized prostate cancer, taking into account a balance between the hypothetical benefit in results in favor of surgery and the different severity of the effects and risks, age and comorbidity, in favor of radiotherapy. We describe the expectant management practices for localized cancer in our environment, as well as the relative proportions for surgery, radiotherapy, brachytherapy, cryotherapy, HIFU, and even hormone blockade in these patients. The still low penetration of PRL, in 1:3 ratio compared to open surgery, is once more evidenced.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> Professionals appreciate the advantages thereof, and even more of the RALRP, although they are very aware of the economic implications that these approaches entail. Concern over issues related to the quality of life of the patients is very high. Erection sparing surgery is one of the points of special interest to the healthcare professional, and it is one of the areas of continuous improvement in the management of these patients. And so is the proper management of patients with biochemical recurrence after failed surgery or radiotherapy.</p><p id="par0115" class="elsevierStylePara elsevierViewall">The data on the use of hormone blockade are very interesting. The professional surveyed overwhelmingly supports the BAM versus monotherapy with LHRH analogue, early hormone treatment, and the use of neoadjuvant and adjuvant hormone therapy for operated patients, and especially for those who are oriented to radiotherapy. It is curious to know how there are also strong preferences regarding the characteristics inherent to the preparation and properties of the different forms of LHRH analogues.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> For the first time, the practices of intermittent hormone blockade are described in our country.</p><p id="par0120" class="elsevierStylePara elsevierViewall">The main point of concern is the development of new therapies for prostate cancer. The professionals may perceive their role in the advent of new forms of secondary hormone manipulation, and they may be aware of their increasingly important role in the treatment decision at all stages of the disease, including castration-resistant prostate cancer.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,17</span></a> On the contrary, the least worrying point revealed in this survey is constituted by robotic surgery and disease prevention.</p><p id="par0125" class="elsevierStylePara elsevierViewall">In summary, this survey shows a significant variability in some points of clinical practice with regard to the recommendations of experts,<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7–10</span></a> highlights the main concerns of professional training, defines opportunities for training improvement, and detects needs in the national urological associations.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Funding</span><p id="par0130" class="elsevierStylePara elsevierViewall">Project supported by the <span class="elsevierStyleGrantSponsor">Spanish Urological Association</span> and made possible by funding from <span class="elsevierStyleGrantSponsor">Abbott Laboratories Inc.</span>, with the support of the company <span class="elsevierStyleGrantSponsor">Luzán 5 Inc.</span></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle">Conflict of interest</span><p id="par0135" class="elsevierStylePara elsevierViewall">The survey UROQUEST, which supports this work, was conducted by Luzán 5 Inc. under the auspices of Abbott Laboratories Inc., taking the opinion of a sample of urologists based on their practice.</p><p id="par0140" class="elsevierStylePara elsevierViewall">The results derived therefrom have been critically analyzed by Drs. Núñez, Javier Angulo, Manuel Sánchez-Chapado, José Antonio Portillo, and Humberto Villavicencio, without any conflict of interest and without receiving any fees for the completion of this work.</p><p id="par0145" class="elsevierStylePara elsevierViewall">Dr. Sara Alonso works at the Medical Department of Abbott Laboratories Inc., Spain.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:2 [ "identificador" => "xres101669" "titulo" => array:5 [ 0 => "Abstract" 1 => "Objectives" 2 => "Material and methods" 3 => "Results" 4 => "Conclusion" ] ] 1 => array:2 [ "identificador" => "xpalclavsec88835" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres101668" "titulo" => array:5 [ 0 => "Resumen" 1 => "Objetivos" 2 => "Material y métodos" 3 => "Resultados" 4 => "Conclusión" ] ] 3 => array:2 [ "identificador" => "xpalclavsec88836" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Materials and method" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Results" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Disease diagnosis" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Disease prevention" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Treatment of the localized disease" ] 3 => array:2 [ "identificador" => "sec0035" "titulo" => "Treatment of the advanced disease" ] 4 => array:2 [ "identificador" => "sec0040" "titulo" => "Defining areas of interest to the professional" ] ] ] 7 => array:2 [ "identificador" => "sec0045" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0050" "titulo" => "Funding" ] 9 => array:2 [ "identificador" => "sec0055" "titulo" => "Conflict of interest" ] 10 => array:2 [ "identificador" => "xack35392" "titulo" => "Acknowledgement" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2012-02-07" "fechaAceptado" => "2012-02-14" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec88835" "palabras" => array:6 [ 0 => "Prostate cancer" 1 => "Diagnosis" 2 => "Treatment" 3 => "Clinical variability" 4 => "Patient" 5 => "Medical professional" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec88836" "palabras" => array:6 [ 0 => "Cáncer de próstata" 1 => "Diagnóstico" 2 => "Tratamiento" 3 => "Variabilidad clínica" 4 => "Paciente" 5 => "Profesional médico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle">Objectives</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To study the opinion of the Spanish urologists regarding the main points in the diagnosis, prevention, quality of life and treatment of prostate cancer.</p> <span class="elsevierStyleSectionTitle">Material and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">An anonymous questionnaire was administered to 290 specialists who represented the urological professional group involved in the management of prostate cancer in Spain. The following were considered in their definition: grade of professional experience, work setting, contractual relation with patient and academic character of the center. The statistical analysis was based on the study of relative frequencies for qualitative variables. The results were interpreted in 2009–2010 and the final report of them was done in 2011.</p> <span class="elsevierStyleSectionTitle">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Response rate collected and correctly transcribed from the forms was 96.9% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>281). This accounts for 10–15% of the national group. Median age was 47.7 (29–69) years and 92% were men. Mean years of professional experience were 19.1 (1–43). Responses collected regarding 153 questions were analyzed. These dealt with: (a) how the diagnosis of the disease was carried out in the setting of the surveyed; (b) the opinions given on the disease prevention; (c) treatment of the localized treatment; (d) treatment of the advanced disease; and (e) the definition of the fields of interest for the professional.</p> <span class="elsevierStyleSectionTitle">Conclusion</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">This survey showed important variability in some points of clinical practice in regard to the recommendations of the experts. It also shows the principal concerns of the professional, defines opportunities for training improvements and detects needs in the national urological group.</p>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span class="elsevierStyleSectionTitle">Objetivos</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Explorar la opinión de los urólogos españoles respecto a los principales puntos en el diagnóstico, prevención, calidad de vida y tratamiento del cáncer de próstata.</p> <span class="elsevierStyleSectionTitle">Material y métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Se administró un cuestionario anónimo a 290 especialistas que representan el colectivo profesional urológico involucrado en el manejo del cáncer de próstata en España. En su definición se tuvo en cuenta el grado de experiencia profesional, el ámbito de trabajo, la relación contractual con el paciente y el carácter académico del centro. El análisis estadístico se basó en el estudio de frecuencias relativas para variables cualitativas. La interpretación de resultados se llevó a cabo en 2009–2010 y el informe de emisión final de los mismos en 2011.</p> <span class="elsevierStyleSectionTitle">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">La tasa de respuesta recogida y correctamente transcrita de los formularios fue del 96,9% (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>281), lo que supone un 10–15% del colectivo nacional. La mediana de edad fue 47,7 (29–69) años y el 92% fueron hombres. La mediana de experiencia profesional fue 19,1 (1–43) años. Se analizan las respuestas recogidas relativas a 153 cuestiones que tratan: (a) cómo se lleva a cabo el diagnóstico de la enfermedad en el entorno de los encuestados; (b) las opiniones vertidas acerca de la prevención de la enfermedad; (c) el tratamiento de la enfermedad localizada; (d) el tratamiento de la enfermedad avanzada; y (e) la definición de campos de interés para el profesional.</p> <span class="elsevierStyleSectionTitle">Conclusión</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Esta encuesta demuestra una importante variabilidad en algunos puntos de la práctica clínica con respecto a las recomendaciones de expertos. Pone también en evidencia las principales preocupaciones del profesional, define oportunidades de mejora formativa y detecta necesidades en el colectivo urológico nacional.</p>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara">Please cite this article as: Núñez C, et al. Variabilidad de la práctica clínica urológica en cáncer de próstata en España. Actas Urol Esp. 2012;36:333–9.</p>" ] ] "multimedia" => array:8 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1139 "Ancho" => 1639 "Tamanyo" => 73710 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Prostate biopsy technique used (initially light colored, repeated in dark).</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 854 "Ancho" => 1583 "Tamanyo" => 59585 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Candidates considered for chemoprophylaxis with dietary supplements (about 90 respondents).</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1187 "Ancho" => 1590 "Tamanyo" => 64135 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Relative indication surgery/radiotherapy in the healthcare practice of the respondents.</p>" ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 1222 "Ancho" => 1590 "Tamanyo" => 70776 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Distribution by frequency with which the professionals pose observation in patients with localized prostate cancer (about 91 respondents).</p>" ] ] 4 => array:7 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1174 "Ancho" => 1549 "Tamanyo" => 56442 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Reality of use of intermittent hormone therapy (about 177 respondents).</p>" ] ] 5 => array:7 [ "identificador" => "fig0030" "etiqueta" => "Figure 6" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr6.jpeg" "Alto" => 1153 "Ancho" => 1590 "Tamanyo" => 69926 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Duration of adjuvant hormone therapy for the locally advanced disease (following light-colored surgery, after dark radiotherapy).</p>" ] ] 6 => array:7 [ "identificador" => "fig0035" "etiqueta" => "Figure 7" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr7.jpeg" "Alto" => 1486 "Ancho" => 2965 "Tamanyo" => 318892 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Medians and confidence intervals of the degree of interest that the different topics arise in the respondents.</p>" ] ] 7 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1. Development of new therapies \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2. Attitude to biochemical failure – continence associated with the treatment – epidemiology of prostate cancer in Spain – PSA-based population screening – Technical optimization of the biopsy \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3. Dilemmas in the treatment decision of localized cancer – current role of hormone blockade \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4. Laparoscopic radical prostatectomy – sexual life of the patient with prostate cancer – Developments in imaging – developments in molecular diagnosis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5. Robotic radical prostatectomy – chemoprophylaxis strategies \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab184228.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Levels of relative interest for the different topics from 1 (maximum) to 5 (minimum).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:17 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer statistics, 2008" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Jemal" 1 => "R. Siegel" 2 => "E. Ward" 3 => "Y. Hao" 4 => "J. Xu" 5 => "T. Murray" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3322/CA.2007.0010" "Revista" => array:6 [ "tituloSerie" => "CA Cancer J Clin" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "71" "paginaFinal" => "96" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18287387" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "El grupo nominal en el entorno sanitario. Quaderns de Salut Publica i Administració de Serveis de Salut 1" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Peiró" 1 => "E. Portella" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2003" "editorial" => "Escola Valenciana d’Estudis per la Salut" "editorialLocalizacion" => "Valencia" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Avances en uro-oncología OncoForum: lo mejor del 2010" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F. Gómez-Veiga" 1 => "A. Alcaraz-Asensio" 2 => "J. Burgos-Revilla" 3 => "J.M. Cózar-Olmo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2011.02.001" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2011" "volumen" => "35" "paginaInicial" => "315" "paginaFinal" => "324" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21453988" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Snowball sampling" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "L.A. Goodman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Math Stat" "fecha" => "1961" "volumen" => "32" "paginaInicial" => "148" "paginaFinal" => "170" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consenso experto sobre el impacto de la nueva evidencia científica disponible sobre Hiperplasia Benigna de Próstata" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Cózar-Olmo" 1 => "C. Hernández-Fernández" 2 => "B. Miñana-López" 3 => "J.H. Amón-Sesmero" 4 => "M. Montlleó-González" 5 => "A. Rodríguez-Antolín" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2012.01.004" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2012" "volumen" => "36" "paginaInicial" => "265" "paginaFinal" => "275" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22475690" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guías de Práctica Clínica en el SNS" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Guía de Práctica Clínica sobre Tratamiento de Cáncer de Próstata" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2008" "editorial" => "Ministerio de Sanidad y Consumo" "editorialLocalizacion" => "Madrid" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guía de la EAU sobre el cáncer de próstata. Parte I: Cribado, diagnóstico y tratamiento del cáncer clínicamente localizado" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Heindenreich" 1 => "J. Bellmunt" 2 => "M. Bolla" 3 => "S. Joniau" 4 => "M. Mason" 5 => "V. Matveev" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2011.04.004" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2011" "volumen" => "35" "paginaInicial" => "501" "paginaFinal" => "514" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21757259" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guía de la EAU sobre el cáncer de próstata. Parte II: Tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Mottet" 1 => "J. Bellmunt" 2 => "M. Bolla" 3 => "S. Joniau" 4 => "M. Mason" 5 => "V. Matveev" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2011.03.011" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2011" "volumen" => "35" "paginaInicial" => "565" "paginaFinal" => "579" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21757258" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical guidelines on prostate cáncer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Heidenreich" 1 => "M. Bolla" 2 => "S. Joniau" 3 => "M.D. Mason" 4 => "V. Matveev" 5 => "N. Mottet" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:2 [ "fecha" => "2010" "editorial" => "European Association of Urology" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "National Comprehensive Cancer Network (NCCN) Guidelines Version 4. Prostate Cancer" ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2011" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Resultados del uso expandido del PCA3 score en una población española con sospecha de cáncer de próstata" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Rubio-Briones" 1 => "A. Fernández-Serra" 2 => "M. Ramírez" 3 => "L. Rubio" 4 => "A. Collado" 5 => "J. Casanova" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2011.04.001" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2011" "volumen" => "35" "paginaInicial" => "589" "paginaFinal" => "596" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21700365" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cáncer de próstata: la revolución de los genes de fusión" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Fernández-Serra" 1 => "J. Rubio-Briones" 2 => "Z. García-Casado" 3 => "E. Solsona" 4 => "J.A. López-Guerrero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2010.11.019" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2011" "volumen" => "35" "paginaInicial" => "420" "paginaFinal" => "428" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21601955" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular detection of prostate cancer in urine by GSTP1 hypermethylation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Cairns" 1 => "M. Esteller" 2 => "J.G. Herman" 3 => "M. Schoenberg" 4 => "C. Jeronimo" 5 => "M. Sanchez-Cespedes" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Cancer Res" "fecha" => "2001" "volumen" => "7" "paginaInicial" => "2727" "paginaFinal" => "2730" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11555585" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prostate cancer: multiparametric MR imaging for detection, localization, and staging" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.M. Hoeks" 1 => "J.O. Barentsz" 2 => "T. Hambrock" 3 => "D. Yakar" 4 => "D.M. Somford" 5 => "S.W. Heijmink" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1148/radiol.11091822" "Revista" => array:6 [ "tituloSerie" => "Radiology" "fecha" => "2011" "volumen" => "261" "paginaInicial" => "46" "paginaFinal" => "66" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21931141" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Perfil descriptivo de la práctica laparoscópica actual en la Urología española" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P. Cabrera" 1 => "E. Hernández" 2 => "C. Núñez" 3 => "F. Cáceres" 4 => "F. Caballero" 5 => "J. Angulo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rev Urol" "fecha" => "2009" "volumen" => "10" "paginaInicial" => "217" "paginaFinal" => "223" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "¿Se ha de asumir el efecto de clase farmacológica entre los diferentes análogos de la hormona liberadora de la hormona luteinizante usados en el tratamiento del carcinoma de próstata?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Vilar-González" 1 => "X. Maldonado-Pijuan" 2 => "I. Andrés-García" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2010" "volumen" => "34" "paginaInicial" => "749" "paginaFinal" => "757" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20843451" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cáncer de próstata resistente a la castración: ¿hacia dónde vamos?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Alcaraz" 1 => "R. Medina" 2 => "P. Maroto" 3 => "M.A. Climent" 4 => "D. Castellano" 5 => "J. Carles" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2011.10.010" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp" "fecha" => "2011" "volumen" => "36" "paginaInicial" => "367" "paginaFinal" => "374" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22188754" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:3 [ "identificador" => "xack35392" "titulo" => "Acknowledgement" "texto" => "<p id="par0150" class="elsevierStylePara elsevierViewall">The authors thank Rafael Alonso for his help in the development of the iconography.</p>" ] ] ] "idiomaDefecto" => "en" "url" => "/21735786/0000003600000006/v1_201304251924/S2173578612001333/v1_201304251924/en/main.assets" "Apartado" => array:4 [ "identificador" => "6273" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735786/0000003600000006/v1_201304251924/S2173578612001333/v1_201304251924/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578612001333?idApp=UINPBA00004N" ]
